Prognostic role of long non-coding RNA HNF1A-AS1 in Chinese cancer patients: a meta-analysis
Authors Zhuang C, Zheng L, Wang P
Received 25 January 2018
Accepted for publication 27 June 2018
Published 31 August 2018 Volume 2018:11 Pages 5325—5332
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Professor Jianmin Xu
Chunbo Zhuang,1 Lei Zheng,1 Pei Wang2
1Department of Clinical Laboratory Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of China; 2Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of China
Background: Long non-coding RNAs (LncRNAs) play important roles in tumorigenesis and progression. Recent studies have demonstrated that LncRNA HNF1A antisense RNA 1 (HNF1A-AS1) is aberrantly expressed in several types of cancers and is associated with poor outcomes. This meta-analysis was conducted to investigate the relationship between HNF1A-AS1 expression and clinical outcomes in cancer patients.
Methods: We searched PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wan Fang databases (updated until December 31, 2017) for literature. A total of eight studies with 789 cancer patients were finally included in the present meta-analysis.
Results: The results showed that high expression of HNF1A-AS1 significantly predicted poor overall survival (HR=3.10, 95% CI: 1.58–6.11, P=0.001), which was further validated using The Cancer Genome Atlas (TCGA) dataset. Moreover, high HNF1A-AS1 expression was also associated with advanced TNM stage (OR=3.32, 95% CI: 2.28–4.83, P<0.001), lymph node metastasis (OR=3.08, 95% CI: 1.95–4.85, P<0.001), and distant metastasis (OR=5.53, 95% CI: 1.94–15.77, P=0.001).
Conclusion: Our results suggested that elevated HNF1A-AS1 was associated with poor clinical outcomes and might serve as a potential prognostic biomarker of cancer.
Keywords: cancer, overall survival, TCGA, long non-coding RNA, HNF1A-AS1, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]